Lexeo Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-12
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$25.87M.
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$20.20M.
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$20.92M.
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$20.28M.
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$99.96M.
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$98.33M.
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$66.39M.
- Lexeo Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$59.28M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$25.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$46.06M 10-Q · filed 2026-08-12 | -$66.98M derived: sum of 3 quarters · filed 2026-08-12 | -$87.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$20.20M 10-Q · filed 2026-05-11 | -$41.12M derived: sum of 2 quarters · filed 2026-05-11 | -$61.40M derived: sum of 3 quarters · filed 2026-05-11 | -$87.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$20.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$41.20M derived: sum of 2 quarters · filed 2026-03-30 | -$67.31M derived: sum of 3 quarters · filed 2026-08-12 | -$99.96M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$20.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$46.39M derived: sum of 2 quarters · filed 2026-08-12 | -$79.04M 10-Q · filed 2025-11-05 | -$104.97M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$26.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$58.76M 10-Q · filed 2026-08-12 | -$84.68M derived: sum of 3 quarters · filed 2026-08-12 | -$114.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$32.66M 10-Q · filed 2026-05-11 | -$58.58M derived: sum of 2 quarters · filed 2026-05-11 | -$88.07M derived: sum of 3 quarters · filed 2026-05-11 | -$109.31M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$25.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$55.41M derived: sum of 2 quarters · filed 2026-03-30 | -$76.65M derived: sum of 3 quarters · filed 2026-03-30 | -$98.33M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$29.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$50.73M derived: sum of 2 quarters · filed 2025-11-05 | -$72.41M 10-Q · filed 2025-11-05 | -$86.60M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$21.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$42.92M 10-Q · filed 2025-08-14 | -$57.11M derived: sum of 3 quarters · filed 2025-08-14 | -$77.22M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$21.68M 10-Q · filed 2025-05-12 | -$35.87M derived: sum of 2 quarters · filed 2025-05-12 | -$55.98M derived: sum of 3 quarters · filed 2025-05-12 | -$69.42M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$14.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$34.30M derived: sum of 2 quarters · filed 2025-03-24 | -$47.74M derived: sum of 3 quarters · filed 2025-03-24 | -$66.39M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$20.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$33.55M derived: sum of 2 quarters · filed 2024-11-13 | -$52.21M 10-Q · filed 2024-11-13 | -$66.78M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$13.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$32.10M 10-Q · filed 2024-08-12 | -$46.68M derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$18.66M 10-Q · filed 2024-05-09 | -$33.23M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$14.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$59.28M 10-K · filed 2024-03-11 | ||
| 2022-09-30 | -$44.70M 10-Q · filed 2023-12-11 |